Deep brain stimulation

Precision Neuroscience Expands Clinical Research In Brain–Computer Interface

Retrieved on: 
Friday, March 22, 2024
Brain, BCI, Motor cortex, Assistant, Associate, Partnership, University, Patient, Deep brain stimulation, DSM-IV codes, Research, Sale, Electrode, Parkinson's disease, Trial of the century, Behavior, Hospital, Optimism, Precision, DBS, Mount Sinai Health System, Movement, Hand, Health, Medical device

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Brain–computer interface (BCI) company Precision Neuroscience Corporation (Precision) today announced the launch of two new clinical study sites, at Mount Sinai Health System and Perelman School of Medicine at the University of Pennsylvania (Penn Medicine).
  • Its design allows for safe implantation and removal by neurosurgeons without causing harm to delicate brain tissue.
  • Dr. Ben Rapoport, Chief Science Officer and co-founder of Precision Neuroscience, underscored the significance of these studies in advancing both medical science and patient care.
  • This partnership aims to explore the diverse applications of high-resolution cortical surface arrays in clinical settings, ranging from intraoperative monitoring to neurocritical care.

Minneapolis Psychiatry Clinic Adds Vagus Nerve Stimulation as Non-Drug Therapy for Severe Depression

Retrieved on: 
Wednesday, March 20, 2024
Mental Health, Surgery, Medical Devices, Alternative Medicine, Health, Vagus nerve, Deep brain stimulation, Depression, DSM-IV codes, Brain, VNS, LivaNova, Vagus nerve stimulation, Patient, TMS, Mental health, Bipolar disorder, Skin, Ketamine, Transcranial magnetic stimulation, Medicare, FDA, CMS

Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.

Key Points: 
  • Advanced Brain + Body Clinic Ketamine TMS (AB+BC), specialists in treatment-resistant depression and other severe mental health conditions, added Vagus Nerve Stimulation (VNS) as an FDA-approved, non-medication treatment option for severe or bipolar depression.
  • VNS has a 70% success rate when used for treatment resistant depression, meaning the patient hasn’t responded to traditional antidepressants.
  • VNS stimulates the vagus nerve, triggering its natural process of sending electrical pulses to the parts of the brain that control mood.
  • For more information about Vagus Nerve Stimulation and what to expect, visit Advanced Brain and Body Clinic’s VNS page .

ClearPoint Neuro Announces FDA Clearance and First-in-Human Cases Performed with the New 2.2 Software Version and the Integrated Maestro Brain Model

Retrieved on: 
Wednesday, February 21, 2024
NeuroImage, Spine, FreeSurfer, FDA, Biopsy, Paper, Surgeon, Manuscript, Deep brain stimulation, Brain, Medical device

“The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.

Key Points: 
  • “The Maestro Brain Model, and its integration into the recently FDA cleared ClearPoint 2.2 navigation software, is our latest example of just that.
  • The ClearPoint system can now offer fast, peri-procedural segmentation of the cortical structures of the brain to identify both targets and safety zones for cell and gene therapy delivery, laser ablation, biopsy and deep brain stimulation.
  • This manuscript introduces the methodology for shape-constrained deformable brain segmentation behind Maestro, describes the validation performed for its FDA clearance, and presents a comparison with manual expert segmentation and FreeSurfer, an open-source segmentation software.
  • Reproducibility error of Maestro (green), FreeSurfer 7.2 (blue) and manual segmentation (red) for common brain structures (left), and average over all structures (right).

Neuroelectrics Announces Results of Telemedicine Pilot Depression Study with Starstim tDCS Therapy

Retrieved on: 
Thursday, March 7, 2024
Science, Biotechnology, Telemedicine, Virtual Medicine, Research, Health, Mental Health, Medical Devices, Clinical Trials, Electrode, Depressive, Multimedia, Preprint, Satisfaction, Grammatical mood, Quick, Deep brain stimulation, Safety, Quality of life, Patient, DSM-IV codes, Harvard Medical School, MDD, Brain, Depression, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20240307614300/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240307614300/en/
    The preprint, titled “Multichannel tDCS with Advanced Targeting for Major Depressive Disorder: A Tele-Supervised At-Home Pilot Study,” highlights results from a multicenter, open-label feasibility telemedicine pilot study that studied the efficacy, safety, and feasibility of home-based tDCS using Starstim to target the L-DLPFC.
  • The study was conducted across multiple centers and involved 35 participants diagnosed with medication-resistant MDD to evaluate tDCS administered at home using Neuroelectrics’ Starstim device.
  • Results from this study highlight the safety and feasibility of at-home tDCS, with nearly 90% of participants completing the treatment without experiencing any adverse effects.
  • “We’re excited to announce the results of our telemedicine pilot study, showcasing the transformative potential of at-home tDCS therapy with our Starstim device in managing MDD,” said Ana Maiques, CEO & Co-Founder, Neuroelectrics.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024
Pulse, Growth, Market development, Research, Abbott Laboratories, Ageing, Tetraplegia, Prevalence, Spinal cord stimulator, Deep brain stimulation, Vagus nerve stimulation, DSM-IV codes, Investment, Parkinson's disease, LivaNova, Competition, Epilepsy, Alzheimer's disease, Boston Scientific, Pharmaceutical industry

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.
  • Market Development: Comprehensive information about lucrative markets – the report analyses the neuromodulation market across varied regions.

Neuromodulation Market Worth $11.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, February 2, 2024
Pulse, Growth, Market development, Research, Abbott Laboratories, Ageing, Tetraplegia, Prevalence, Spinal cord stimulator, Deep brain stimulation, Vagus nerve stimulation, DSM-IV codes, Investment, Parkinson's disease, Epilepsy, Competition, Alzheimer's disease, Boston Scientific, Pharmaceutical industry

The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.

Key Points: 
  • The global neuromodulation market is segmented into internal neuromodulation and external neuromodulation based on type.
  • In 2022, internal neuromodulation dominated the global neuromodulation market.
  • The spinal cord stimulation segment accounted for the largest share of the neuromodulation market, by internal neuromodulation type, in 2022.
  • Increasing collaborations among device manufacturers, healthcare providers, and research institutions to develop neuromodulation devices
    Key Market Players of Neuromodulation Industry:
    The break-up of the profile of primary participants in the neuromodulation market:
    Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=921
    Neuromodulation Market - Key Benefits of Buying the Report:
    The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall neuromodulation market and the subsegments.

Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+

Retrieved on: 
Thursday, January 25, 2024
Patient, Research, DBS, DSM-IV codes, Communication, University, Parkinson's disease, PINS, Food, Deep brain stimulation, Travel, Movement, Neurosurgery, FDA, Wi-Fi, Boston Scientific, Essential tremor, Movement disorder, IOS, Use

"The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.

Key Points: 
  • "The Liberta RC DBS system excels in both areas, as a compact rechargeable device with the lowest recharge requirement of any FDA-approved DBS system.
  • This achievement, coupled with the integration of remote programming capabilities, is a significant advancement for patients."
  • "In developing the Liberta RC DBS system, our focus has been on the unique experiences of individuals with chronic conditions like movement disorders," said Pedro Malha, vice president, neuromodulation, Abbott.
  • This system exemplifies our drive to providing patient-first solutions, combining effective therapy, effortless recharging, and remote programming capabilities."

AHN team performs region's first deep brain stimulation therapy to treat opioid addiction

Retrieved on: 
Saturday, January 13, 2024
AHN, Death, Obesity, Learning, Drug, Patient, Addiction, Research, DBS, Electrode, Multimedia, DSM-IV codes, Accident, Fentanyl, COVID, Xylazine, Parkinson's disease, IRB, Heroin, Deep brain stimulation, Food, AGH, Allegheny Health Network, Myenteric plexus, FDA, Opioid, Nucleus accumbens, Public, Addiction medicine, Institutional review board, Brain, Trial of the century, Physician, Pharmaceutical industry

PITTSBURGH, Jan. 13, 2024 /PRNewswire-PRWeb/ -- A multidisciplinary team of physicians at Allegheny Health Network (AHN) is among the first in the nation to safely utilize deep brain stimulation therapy (DBS) to treat a patient suffering from opioid addiction.

Key Points: 
  • PITTSBURGH, Jan. 13, 2024 /PRNewswire-PRWeb/ -- A multidisciplinary team of physicians at Allegheny Health Network (AHN) is among the first in the nation to safely utilize deep brain stimulation therapy (DBS) to treat a patient suffering from opioid addiction.
  • Led by principal investigator and AHN neurosurgeon Nestor D. Tomycz, MD, the AHN team announced this week that they have successfully implanted an deep brain stimulation (DBS) device in the brain of a 28-year-old New York man with treatment-resistant opioid addiction.
  • The procedure took place in December at AHN's Allegheny General Hospital, and the patient's ongoing therapy is part of an FDA-approved clinical study.
  • DBS for opioid-use disorder involves implanting bilateral electrode leads into an area of the brain called the nucleus accumbens – the brain's addiction and reward center.

FDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology

Retrieved on: 
Monday, January 8, 2024
Patient, University, Essential tremor, Food, Parkinson's disease, Movement, Software, Epilepsy, FDA, Deep brain stimulation, CE marking, Neuroscience, Freedom, RC, Medtronic, Neurology, DBS, FAAN, Dystonia, Neuromodulation, DSM-IV codes, Medical imaging

DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system. The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology†, and SenSight™ directional leads. The Percept™ family is the only sensing-enabled DBS system on the market, allowing the physician to personalize treatment for patients with movement disorders such as Parkinson's disease, essential tremor, and dystonia* as well as epilepsy. Over 11 million people in the U.S. are living with movement disorders1-2 and approximately 3.4 million with epilepsy3.

Key Points: 
  • DUBLIN, Jan. 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its Percept™ RC Deep Brain Stimulation (DBS) system.
  • The rechargeable neurostimulator is the latest innovation in the Medtronic Percept™ family, which includes the Percept™ PC neurostimulator, BrainSense™ technology†, and SenSight™ directional leads.
  • Percept™ RC is available immediately throughout the U.S., as well as via CE Mark approval in Europe and availability in Japan.
  • For further information on the Percept™ neurostimulators with exclusive BrainSense™ technology, visit our website here .

Synchron Appoints Riki Banerjee as Chief Technology Officer

Retrieved on: 
Wednesday, January 3, 2024
Science, Biotechnology, Research, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, Master, BCI, Multimedia, Electricity, Paralysis, Brain, Spinal cord stimulator, University, Engineering, Deep brain stimulation, Doctor of Philosophy, Growth, Patient, Disability studies, Medical device

Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).

Key Points: 
  • Synchron , the endovascular brain-computer interface (BCI) company developing technology designed to restore functionality in patients with motor impairment, today announced the appointment of Riki Banerjee, Ph.D., to Chief Technology Officer (CTO).
  • Banerjee will be responsible for leading all research and development (R&D) activities, including advancing Synchron’s neuroprosthesis device for patients with severe paralysis.
  • Banerjee will succeed Nick Opie, Ph.D., the founding CTO and co-founder of Synchron who remains on the Board of Directors.
  • Riki has led teams across engineering and scientific disciplines to translate medical technology to commercialized product.